Gastrointestinal Cancer | Specialty

Experts Provide Insight on Aspects of Cancer Care That Are Not as Widespread in Community Practice

November 1st 2019

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

Hepatic Infusion Can Convert CRC Liver Metastases to Operable State

November 1st 2019

Overall, compelling response rates and rates of conversion to resection for patients with initially unresectable colorectal liver metastases treated with hepatic arterial infusion suggest consideration of earlier initiation of the technique in chemotherapy-naïve patients as well as its adoption in patients who have failed first-line systemic chemotherapy before proceeding to second- or third-line regimens.

Dr. Abou-Alfa on the Results of the ClarIDHy Trial in Advanced Cholangiocarcinoma

November 1st 2019

Ghassan K. Abou-Alfa, MD, discusses the results of the phase III ClarIDHy trial in advanced cholangiocarcinoma.

Deeper Understanding of NETs Biology May Hold Key to Therapeutic Advances

October 31st 2019

Lakshmi N. Rajdev, MD, discusses classifying and grading neuroendocrine tumors (NETs), treating patients with NETs, and novel therapeutic strategies in the pipeline.

MRTX849 Active in KRAS G12C+ NSCLC and CRC

October 29th 2019

The investigational KRAS G12C inhibitor MRTX849 demonstrated clinical activity in patients with non–small cell lung cancer and colorectal cancer.

Targeting Wnt in BRAF-Mutant Colorectal Cancer

October 28th 2019

Luke Dow, PhD, discusses phase I trials targeting the Wnt signaling pathway in colorectal cancer.

FDA Will Split Avapritinib GIST NDA Into Separate Submissions

October 28th 2019

The FDA has informed Blueprint Medicines that it intends to split the proposed indications for its agent avapritinib into two separate new drug applications for patients with gastrointestinal stromal tumor (GIST): one for patients with PDGFRA exon 18–mutant disease regardless of prior therapy, and one for fourth-line GIST.

MCLA-128 Shows Clinical Activity in NRG1+ Solid Tumors

October 28th 2019

MCLA-128, an investigational bispecific HER2/HER3 antibody, demonstrated radiological and clinical responses in patients with metastatic pancreatic ductal adenocarcinoma and metastatic non–small cell lung cancer who have NRG1 fusions.

Addressing the Needs of Molecular Subgroups in CRC

October 28th 2019

Benjamin Weinberg, MD, discusses the treatment options available for the various subpopulations in metastatic colorectal cancer.

Dr. Corcoran on Immunotherapy for Microsatellite Stable/Instable CRC

October 26th 2019

Ryan B. Corcoran, MD, PhD, discusses immunotherapy options for patients with microsatellite stable versus microsatellite instability–high colorectal cancer.

Ongoing Research in Pancreatic Cancer Focusing on Molecular Targets

October 25th 2019

Eileen M. O’Reilly, MD, discusses emerging strategies in pancreatic cancer.

Dr. Benson on Sequencing Strategies with Cetuximab in CRC

October 25th 2019

Al B. Benson, MD, discusses the optimal sequencing of the EGFR inhibitor cetuximab for patients with RAS wild-type colorectal cancer.

Early Findings Support Novel Regimen for Unresectable HCC

October 24th 2019

Atezolizumab (Tecentriq) plus bevacizumab (Avastin) resulted in clinically meaningful and durable objective responses as first-line therapy for patients with previously untreated, unresectable disease.

Pivotal Study Examines Blood Test as CRC Screening Method

October 24th 2019

In an effort to improve colorectal cancer screening rates via a less invasive method, the registrational ECLIPSE is evaluating the performance of the LUNAR-2 blood test in detecting colorectal cancer in average-risk adults.

Dr. Kasi on the Prognostic Value of ctDNA in CRC

October 24th 2019

Pashtoon M. Kasi, MD, MBBS, MS, discusses the prognostic value of circulating tumor DNA in colorectal cancer.

Dr. Bekaii-Saab on the Rationale to Explore Tucatinib/Trastuzumab in HER2-Overexpressing mCRC

October 23rd 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the rationale to explore the combination of tucatinib and trastuzumab (Herceptin) in patients with HER2-overexpressing metastatic colorectal cancer.

Pivoting Away From the Biomarker Hunt in Gastric Cancer

October 23rd 2019

David H. Ilson, MD, PhD, discusses current treatment options for patients with gastric cancer, the challenges with the KEYNOTE-062 trial, and other immunotherapy agents coming down the pipeline.

Hepatocellular Carcinoma: Future Directions in Care

October 23rd 2019

Perioperative Approaches to HCC Management

October 23rd 2019

Optimal Sequencing of I/O Therapy in Liver Cancer

October 23rd 2019